Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Dapagliflozin was found to improve glycaemic control and body weight without an increase in the risk of hypoglycemia in the DEPICT studies. No notable change from baseline was seen in eGFR. Dedicated prospective studies are needed to confirm these findings.
